Direct Renin Inhibition Effects on Atherosclerotic Biomarkers

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calcium channel blocker.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Texas Tech University Health Sciences Center
• Treatments: Amlodipine

Criteria

Inclusion Criteria:

• Diagnosis of type 2 diabetes

• Diagnosis of coronary artery disease

• Currently receiving therapy with an ACE-Inhibitor or Angiotensin Receptor Blocker

• Currently receiving antiplatelet therapy and statin therapy

• Baseline blood pressure > 100/75 mm Hg

• BMI 25-35 kg/m2

Exclusion Criteria:

• Concurrent calcium channel blocker therapy

• Documented peripheral edema

• Hyperkalemia

• Serum creatinine > 2.0

• Diagnosed with proteinuria

• Diagnosed with liver dysfunction or serious rheumatological disorder